Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks

Page 6 of 15

10. Adaptive Biotechnologies Corporation (NASDAQ:ADPT)

Number of Hedge Fund Holders: 19

Viking Global’s Stake: $153.6 million  

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is a commercial-stage company developing an immune medicine platform for the diagnosis and treatment of various diseases. The company stands out as a worthwhile investment due to these factors. Firstly, the reports of the third quarter of 2024 showed impressive results which holds great potential for investors. For instance, the company obtained an updated Medicare Clinical Laboratory Fee Schedule (CLFS) Gapfill Determination for clonoSEQ of $2,007 per test, a 17% increase from the previous implied rate under the episode structure. This increase could lead to higher repayment rates for the company, boosting revenue and profitability. Additionally, the company also received expanded Medicare coverage of clonoSEQ for assessing measurable residual disease in Mantle Cell Lymphoma. This may hold investment potential as the company’s products are influencing healthcare positively, which may impact patient adoption and market share. Secondly, Adaptive Biotechnologies Corporation and NeoGenomics have announced a multi-year exclusive strategic commercial collaboration that will advance minimal residual disease (MRD) monitoring options for patients with select blood cancers, which aims to empower oncologists and pathologists to deliver the highest quality patient care.

Page 6 of 15